Loading
A phase 2 trial of epirubicin, pirarubicin and cyclophosphamide in triple-negative breast cancer, run by Chinese Academy of Medical Sciences, now recruiting.
Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy is a phase 2, randomised interventional study registered as NCT04437160 by Chinese Academy of Medical Sciences, with a registry enrolment figure of 286 participants, started 2020-02-01 and due to reach its primary completion in 2026-01. Interventions recorded: Epirubicin or Pirarubicin; Cyclophosphamide. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "* Triple negative breast cancer: hormone receptor negative (ER \< 10% and PgR \< 10%) and HER2 negative (IHC 0/1+ or ISH non-amplified), as defined by the local pathology laboratory". Sites: China. No results are recorded here; the registry entry is the source.
Shares Epirubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Epirubicin, Cyclophosphamide, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Epirubicin, Cyclophosphamide, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Epirubicin, Cyclophosphamide, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Epirubicin, Cyclophosphamide, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Epirubicin, Cyclophosphamide, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Epirubicin, Cyclophosphamide, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Epirubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.